Form 8.3 - NEKTAR THERAPEUTICS

RNS Number : 6806C
Barclays PLC
12 October 2022
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

NEKTAR THERAPEUTICS

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

11 Oct 2022

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

USD 0.0001 common

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

143,668

0.08%

201,861

0.11%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

7,807,554

4.17%

0

0.00%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

4,800

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

7,956,022

4.25%

201,861

0.11%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

USD 0.0001 common

Purchase

1

3.6400  USD

USD 0.0001 common

Purchase

100

3.4900  USD

USD 0.0001 common

Purchase

100

3.5050  USD

USD 0.0001 common

Purchase

100

3.6450  USD

USD 0.0001 common

Purchase

100

3.5800  USD

USD 0.0001 common

Purchase

200

3.5850  USD

USD 0.0001 common

Purchase

200

3.5700  USD

USD 0.0001 common

Purchase

400

3.5650  USD

USD 0.0001 common

Purchase

400

3.5575  USD

USD 0.0001 common

Purchase

439

3.6451  USD

USD 0.0001 common

Purchase

500

3.6430  USD

USD 0.0001 common

Purchase

501

3.6469  USD

USD 0.0001 common

Purchase

525

3.6128  USD

USD 0.0001 common

Purchase

700

3.5514  USD

USD 0.0001 common

Purchase

975

3.5401  USD

USD 0.0001 common

Purchase

1,400

3.5971  USD

USD 0.0001 common

Purchase

3,188

3.5301  USD

USD 0.0001 common

Purchase

7,841

3.5440  USD

USD 0.0001 common

Purchase

10,508

3.5348  USD

USD 0.0001 common

Purchase

12,295

3.5177  USD

USD 0.0001 common

Purchase

14,681

3.5861  USD

USD 0.0001 common

Purchase

39,455

3.5507  USD

USD 0.0001 common

Purchase

59,409

3.5600  USD

USD 0.0001 common

Sale

100

3.5200  USD

USD 0.0001 common

Sale

100

3.5000  USD

USD 0.0001 common

Sale

300

3.5300  USD

USD 0.0001 common

Sale

721

3.5019  USD

USD 0.0001 common

Sale

900

3.5700  USD

USD 0.0001 common

Sale

1,668

3.5064  USD

USD 0.0001 common

Sale

1,704

3.4987  USD

USD 0.0001 common

Sale

2,000

3.5340  USD

USD 0.0001 common

Sale

2,382

3.5222  USD

USD 0.0001 common

Sale

2,400

3.5270  USD

USD 0.0001 common

Sale

4,601

3.5313  USD

USD 0.0001 common

Sale

5,230

3.5825  USD

USD 0.0001 common

Sale

6,408

3.5461  USD

USD 0.0001 common

Sale

9,887

3.5369  USD

USD 0.0001 common

Sale

13,526

3.5815  USD

USD 0.0001 common

Sale

16,445

3.5696  USD

USD 0.0001 common

Sale

29,804

3.5600  USD

USD 0.0001 common

Sale

40,596

3.5487  USD

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i)  the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

Date of disclosure:

12 Oct 2022

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO

PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

1.

KEY INFORMATION

Identity of the person whose positions/dealings

Barclays PLC.

are being disclosed:

Name of offeror/offeree in relation to whose

NEKTAR THERAPEUTICS

relevant securities this from relates:

 

 

 

 

 

 

 

 

2.

OPTIONS AND DERIVATIVES

Class of relevant security

Product description

Writing, purchasing, selling, varying etc

Number of securities to which option relates

Exercise price per unit

Type

Expiry date

USD 0.0001 common

Call Options

Purchased

500

22.0000

American

16 Dec 2022

USD 0.0001 common

Call Options

Purchased

4,300

20.0000

American

16 Dec 2022

 

 

 

 

 

 

 

 

3.

AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETBKBBNBBDDNKD

Companies

Barclays (BARC)
UK 100